Company / Operating Cash Flow
NeoGenomics Laboratories, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$5.2M
FY2025
5-year range
-$66.0M / $7.0M
FY2021-FY2025
Trend
-25.5%
vs FY2024
Sector context
#138 of 164
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s operating cash flow of $5M is lower than 84% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$66M in FY2022 to $45M in FY2018.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of +29.1%.
Improved from -$2M to $5M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +29.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 164This company $5.2M Sector average $1.0B
▼
-99.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +29.1%, indicating consistent growth.
- In FY2025, operating cash flow decreased 25.5% year-over-year.
- Ranks #138 out of 164 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.2M | -25.5% |
| FY2024 | $7.0M | +459.6% |
| FY2023 | -$2.0M | +97.0% |
| FY2022 | -$66.0M | -147.0% |
| FY2021 | -$26.7M | -1930.3% |
| FY2020 | $1.5M | -93.8% |
| FY2019 | $23.4M | -47.8% |
| FY2018 | $44.8M | +148.3% |
| FY2017 | $18.0M | -16.0% |
| FY2016 | $21.5M | +235.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026